Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NeoGenomics, Inc.

< Previous 1 2 3 Next >
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Reports Third Quarter 2025 Results
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Reports Second Quarter 2025 Results
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Participate in Upcoming June Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Pays Off 1.25% Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Reports First Quarter 2025 Results
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Completes Acquisition of Pathline
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Announces Chief Executive Officer Succession
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.